Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genovate Biotechnology Co's total inventories for the quarter that ended in Dec. 2025 was NT$143.8 Mil. Genovate Biotechnology Co's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Dec. 2025 was NT$147.3 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Genovate Biotechnology Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was NT$4.11.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Genovate Biotechnology Co's Days Inventory for the
three
months ended in Dec. 2025 was 170.60.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Genovate Biotechnology Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.53.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genovate Biotechnology Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 1.23.
Genovate Biotechnology Co (ROCO:4130) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Genovate Biotechnology Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genovate Biotechnology Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Genovate Biotechnology Co Total Inventories Related Terms
Genovate Biotechnology Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovate Biotechnology Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of NT$143.8 Mil mean?
Genovate Biotechnology Co (ROCO:4130) has a Total Inventories of NT$143.8 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Genovate Biotechnology Co and its competitors.
Is Genovate Biotechnology Co's Total Inventories too high?
Genovate Biotechnology Co's current Total Inventories is NT$143.8 Mil. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Total Inventories compare to VRTX and REGN?
Genovate Biotechnology Co's Total Inventories of NT$143.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current Total Inventories is NT$143.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current Total Inventories is NT$143.8 Mil. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Total Inventories is NT$143.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?
Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued.
The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20.
GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4130:
Total Inventories: NT$143.8 Mil
GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score
Get the complete analysis for ROCO:4130
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4130 has been successfully added to your 
